Table 2.
Summary of Principal Outcome Analysis for D2FS increment
| Xylitol | Placebo | Rate Ratio1 | 95% CI1 | p-value1 | |
|---|---|---|---|---|---|
| Excluding UTHSCSA | |||||
| n=218 | n=219 | ||||
| follow-up (years)2,3 | 2.54 (.55) | 2.58 (.50) | |||
| baseline D2FS score2 | 21.3(13.6) | 21.4 (13.3) | |||
| annualized D2FS increment4 | 2.69 | 2.98 | 0. 90 | (0.78, 1.03) | 0.14 |
| Including UTHSCSA | |||||
| n=331 | n=338 | ||||
| follow-up (years)2,3 | 2.55 (.49) | 2.57 (.47) | |||
| baseline D2FS score2 | 18.8 (12.8) | 18.5 (12.5) | |||
| annualized D2FS increment4,5 | 2.64 | 2.96 | 0.89 | (0.80, 1.01) | 0.063 |
1
based on negative binomial model adjusting for age at randomization, age-squared, dental cleaning or exam in the last 12 months, OTC fluoride use, usually brush/floss, baseline severity, site
2
data expressed as mean (SD)
3
time from baseline to last observed follow-up visit
4
includes imputed data (from baseline to first annual visit) for 22 individuals from UAB or UNC with no follow-up data
5
based on analysis excluding an additional 5 individuals with missing covariate data